Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of AIM ImmunoTech's Ampligen?
Ampligen is an oligonucleotide commercialized by AIM ImmunoTech, with a leading Phase III program in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)....
Data Insights
Risk adjusted net present value: What is the current valuation of AIM ImmunoTech's Ampligen?
Ampligen is an oligonucleotide commercialized by AIM ImmunoTech, with a leading Phase III program in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)....